Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrEP-001 influenza A(H3N2) prophylaxis challenge study
2015-002895-26Phase 2Completed
- Sponsor
- hVIVO
- Start
- Aug 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in influenza comparing PrEP-001 with Placebo (2 arms). Primary endpoint: Area under the curve of total symptom score. Started Aug 2015; status: completed.
02
Drugs
polyinosine-polycytidylic acid
03
Conditions
influenza
Beyond the preview
Go deeper on 2015-002895-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002895-26.